目的探讨乳腺癌组织中miRNA-92a、KLF4 mRNA的表达及与临床病理参数、预后的关系。方法选取2014年1月—2016年9月长沙市第一医院乳甲外科收治的124例乳腺癌患者。qRT-PCR检测癌组织和距离>5 cm的癌旁组织中miR-92a、KLF4 m RNA表达;P...目的探讨乳腺癌组织中miRNA-92a、KLF4 mRNA的表达及与临床病理参数、预后的关系。方法选取2014年1月—2016年9月长沙市第一医院乳甲外科收治的124例乳腺癌患者。qRT-PCR检测癌组织和距离>5 cm的癌旁组织中miR-92a、KLF4 m RNA表达;Pearson相关性分析乳腺癌组织中miR-92amRNA表达与KLF4 m RNA表达的相关性;绘制不同miR-92a、KLF4 mRNA表达乳腺癌患者的生存曲线;多因素Cox回归分析乳腺癌患者预后不良影响因素。结果癌组织miR-92a、KLF4 mRNA相对表达量高于癌旁组织(P<0.05)。Pearson相关性分析显示,乳腺癌组织中miR-92a与KLF4 mRNA表达呈正相关(r=0.612,P<0.05)。临床分期Ⅲ、Ⅳ期和有淋巴结转移患者的miR-92a、KLF4 mRNA表达水平高于临床分期Ⅰ、Ⅱ期和无淋巴结转移患者(P<0.05)。不同年龄、肿瘤直径、分化程度、雌激素受体、孕激素受体患者miR-92a、KLF4 mRNA相对表达量比较,差异无统计学意义(P>0.05)。miR-92a、KLF4 mRNA相对表达量高表达患者累积生存率低于低表达患者(P<0.05)。多因素Cox回归分析显示,临床分期Ⅲ、Ⅳ期[HR=3.716(95%CI:1.765,7.826)]、淋巴结转移[HR=3.021(95%CI:1.341,6.803)]、miR-92a≥1.627[HR=3.401(95%CI:1.358,8.515)]、KLF4 mRNA≥2.270[HR=2.059(95%CI:1.026,4.133)]是乳腺癌患者预后不良的危险因素(P<0.05)。结论乳腺癌组织中miR-92a、KLF4 m RNA高表达与临床分期、淋巴结转移有关,可能成为乳腺癌预后的标志物。展开更多
Background： The clotting system abnormalities are the common complication in cancer patients. The aim of this retrospective study was to evaluate the coagulation state, clinical features, and treatment in cancer pati...Background： The clotting system abnormalities are the common complication in cancer patients. The aim of this retrospective study was to evaluate the coagulation state, clinical features, and treatment in cancer patients by routine tests. Methods： A total of 2328 patients with different types of cancer were classified as the positive group （n = 1419, including 53 patients with thrombosis） and the negative group （n = 909） based on D-dimer （DD） value. Of the 2328 cases, 354 were admitted for chemotherapy. Hemostasis test and complete blood count （CBC） were perfbrmed during treatment or following-up. Results： This study showed that the hypercoagulable state was affected not only by clinical staging （P 〈 0,0001） but also by metastasis site （P 〈 0.0001 for bone vs. lung）. Compared to negative DD group, the higher fibrinogen level, the extended activated partial thromboplastin time, and prothrombin time interacted markedly with disease clinical stage （P 〈 0.05） in the positive group. Between positive DD groups with and without thrombus, the significantly statistic difference in white blood cell （WBC） and DD （P 〈 0.05） rather than in red blood cell （RBC） and platelet count was observed. However, the higher DD level was not correlated with WBC, RBC, and platelet count in the positive DD group. Furthermore, the hypercoagulable plasma profile in cancer patients was moderated 2-3 weeks alter chemotherapy （P 〈 0.05 for first six cycles）. Conclusions： The routine hemostatic parameters and CBC are valuable to assessment for thrombosis and chemotherapy even for disease prognosis.展开更多
文摘Background： The clotting system abnormalities are the common complication in cancer patients. The aim of this retrospective study was to evaluate the coagulation state, clinical features, and treatment in cancer patients by routine tests. Methods： A total of 2328 patients with different types of cancer were classified as the positive group （n = 1419, including 53 patients with thrombosis） and the negative group （n = 909） based on D-dimer （DD） value. Of the 2328 cases, 354 were admitted for chemotherapy. Hemostasis test and complete blood count （CBC） were perfbrmed during treatment or following-up. Results： This study showed that the hypercoagulable state was affected not only by clinical staging （P 〈 0,0001） but also by metastasis site （P 〈 0.0001 for bone vs. lung）. Compared to negative DD group, the higher fibrinogen level, the extended activated partial thromboplastin time, and prothrombin time interacted markedly with disease clinical stage （P 〈 0.05） in the positive group. Between positive DD groups with and without thrombus, the significantly statistic difference in white blood cell （WBC） and DD （P 〈 0.05） rather than in red blood cell （RBC） and platelet count was observed. However, the higher DD level was not correlated with WBC, RBC, and platelet count in the positive DD group. Furthermore, the hypercoagulable plasma profile in cancer patients was moderated 2-3 weeks alter chemotherapy （P 〈 0.05 for first six cycles）. Conclusions： The routine hemostatic parameters and CBC are valuable to assessment for thrombosis and chemotherapy even for disease prognosis.
